Pasithea Therapeutics Corp (KTTA) Stock Analysis

AI analysis of Pasithea Therapeutics Corp (KTTA)

Sell

Pasithea Therapeutics Corp (KTTA) is not a good buy right now due to its significant financial losses and weak technical indicators. The current price is $0.37, which is near its 52-week low of $0.28, indicating a poor performance with a year-to-date change of -69.08%. Additionally, the RSI is at 27.41, suggesting that the stock is oversold, but this does not guarantee a rebound. The company has been consistently reporting negative net income, with a loss of $10,110,868 in Q4 2025, which raises concerns about its financial health. The main risk is the ongoing negative earnings trend, as indicated by the projected EPS of -0.21 for the upcoming earnings report on November 12, 2026.

Valuation Metrics

The current forward P/E ratio for Pasithea Therapeutics Corp (KTTA) is 0.00, compared to its 5-year average forward P/E of -3.67.

Forward P/E

Fair

5Y Average P/E

-3.67

Current P/E

0.00

Overvalued

5.56

Undervalued

-12.89

Forward EV/EBITDA

Fair

5Y Average EV/EBITDA

0.18

Current EV/EBITDA

0.00

Overvalued

5.70

Undervalued

-5.34

Forward P/S

Fair

5Y Average P/S

6.24

Current P/S

0.00

Overvalued

20.18

Undervalued

-7.69

Alphio AI Price Scenarios for KTTA

Scenario prices are the last monthly forecast band of the current year. Probabilities are fixed model weights (25 / 50 / 25), not guarantees.

B

Bull

Bull · 25%KTTA

$0.95

Scenario price

B

Base

Base · 50%KTTA

$0.83

Scenario price

B

Bear

Bear · 25%KTTA

$0.78

Scenario price

Whales holding KTTA

C

Cable Car Capital LLC

+ HoldingKTTA

+0.00%

3M Return

KTTA FAQ — answered by Alphio AI

Pasithea Therapeutics Corp. is a biotechnology company focused on the discovery, research, and development of treatments for central nervous system (CNS) disorders and other diseases. The Company is advancing a pipeline of three therapeutic product candidates, with a focus on its lead product candidate, PAS-004, a macrocyclic mitogen-activated protein kinase, or MEK inhibitor. PAS-004 is a small molecule allosteric inhibitor of MEK 1 and 2 (MEK 1/2) for potential use in the treatment of a range of RASopathies, including neurofibromatosis type 1 (NF1) and a number of oncology indications, among others. Its remaining two programs, PAS-001 and PAS-003, are in the earlier stages of development and are based on novel targets for the treatment of CNS disorders that it believes address limitations in the treatment paradigm of the indications it plans to address, which are amyotrophic lateral sclerosis (ALS) for its PAS-003 program, and schizophrenia for its PAS-001 program. It operates in the Healthcare sector (PHARMACEUTICAL PREPARATIONS industry).

Pasithea Therapeutics Corp (KTTA) is not a good buy right now due to its significant financial losses and weak technical indicators. The current price is $0.37, which is near its 52-week low of $0.28, indicating a poor performance with a year-to-date change of -69.08%. Additionally, the RSI is at 27.41, suggesting that the stock is oversold, but this does not guarantee a rebound. The company has been consistently reporting negative net income, with a loss of $10,110,868 in Q4 2025, which raises concerns about its financial health. The main risk is the ongoing negative earnings trend, as indicated by the projected EPS of -0.21 for the upcoming earnings report on November 12, 2026.